📊 KLRS Key Takeaways
Is Kalaris Therapeutics, Inc. (KLRS) a Good Investment?
Kalaris Therapeutics exhibits severe fundamental distress with $165K revenue, $11.6M quarterly cash burn, and approximately 9 months of liquidity runway at current burn rates. While the balance sheet is unencumbered ($34.4M cash, zero debt) and losses are improving 94.5% YoY, the company faces critical refinancing or partnership requirements within 12 months absent significant clinical/commercial catalysts. Pre-revenue biotech operations are only viable with clear pathway to inflection or capital adequacy.
Kalaris is effectively pre-revenue with large operating losses, but it holds a strong, debt-free balance sheet and ample liquidity to fund development for multiple years at the current burn. EPS improvement appears optical given similar net losses, so profitability remains distant without clinical or partnership inflection. Fundamentals warrant patience: balance sheet is solid, but cash burn and execution risks are elevated until revenue visibility emerges.
Kalaris Therapeutics, Inc. Key Strengths (KLRS)
- Strong balance sheet with $34.4M cash and zero long-term debt
- Excellent liquidity position with 12.19x current ratio
- Operating losses improving significantly (94.5% YoY improvement in EPS)
- Cash & equivalents ~$98M supporting ~2–3 years of runway at current burn
- Debt-free capital structure (Debt/Equity 0.00x)
- Very strong liquidity (Current/Quick ratio 12.23x)
KLRS Stock Risks: Kalaris Therapeutics, Inc. Investment Risks
- Critical cash burn rate of ~$11.6M per quarter with only ~9 months of unencumbered runway
- Negligible revenue generation ($165K) with no visible near-term monetization pathway
- Extreme refinancing risk and high probability of shareholder dilution via equity raise or adverse financing terms
- Absence of long-term debt suggests potential difficulty accessing capital markets
- Sustained negative FCF and operating losses with minimal revenue
- Financing/dilution risk if timelines slip or burn increases
- Clinical/regulatory execution risk typical of development-stage biotech
Key Metrics to Watch
- Quarterly cash burn rate trend and runway extension
- Clinical trial progression and regulatory catalysts
- Partnership or financing announcements
- Quarterly revenue growth and customer acquisition
- Quarterly operating cash burn (OCF)
- Cash & equivalents and implied runway (months)
Kalaris Therapeutics, Inc. (KLRS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.19x current ratio provides a solid financial cushion.
KLRS Profit Margin, ROE & Profitability Analysis
KLRS vs Healthcare Sector: How Kalaris Therapeutics, Inc. Compares
How Kalaris Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kalaris Therapeutics, Inc. Stock Overvalued? KLRS Valuation Analysis 2026
Based on fundamental analysis, Kalaris Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kalaris Therapeutics, Inc. Balance Sheet: KLRS Debt, Cash & Liquidity
KLRS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kalaris Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-51.77 indicates the company is currently unprofitable.
KLRS Revenue Growth, EPS Growth & YoY Performance
KLRS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $165.0K | -$2.5M | N/A |
| Q2 2020 | $165.0K | -$2.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kalaris Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
KLRS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kalaris Therapeutics, Inc. (CIK: 0001754068)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KLRS
What is the AI rating for KLRS?
Kalaris Therapeutics, Inc. (KLRS) has a Combined AI Grade of C from Claude (D) and ChatGPT (B) with 69% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KLRS's key strengths?
Claude: Strong balance sheet with $34.4M cash and zero long-term debt. Excellent liquidity position with 12.19x current ratio. ChatGPT: Cash & equivalents ~$98M supporting ~2–3 years of runway at current burn. Debt-free capital structure (Debt/Equity 0.00x).
What are the risks of investing in KLRS?
Claude: Critical cash burn rate of ~$11.6M per quarter with only ~9 months of unencumbered runway. Negligible revenue generation ($165K) with no visible near-term monetization pathway. ChatGPT: Sustained negative FCF and operating losses with minimal revenue. Financing/dilution risk if timelines slip or burn increases.
What is KLRS's revenue and growth?
Kalaris Therapeutics, Inc. reported revenue of $165.0K.
Does KLRS pay dividends?
Kalaris Therapeutics, Inc. does not currently pay dividends.
Where can I find KLRS SEC filings?
Official SEC filings for Kalaris Therapeutics, Inc. (CIK: 0001754068) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KLRS's EPS?
Kalaris Therapeutics, Inc. has a diluted EPS of $-0.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KLRS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Kalaris Therapeutics, Inc. has a C grade with 69% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is KLRS stock overvalued or undervalued?
Valuation metrics for KLRS: ROE of -15.8% (sector avg: 15%), net margin of -6,579.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KLRS's AI grade for 2026?
Our dual AI analysis gives Kalaris Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KLRS's free cash flow?
Kalaris Therapeutics, Inc.'s operating cash flow is $-11.6M, with capital expenditures of $200.0K. FCF margin is -7,140.0%.
How does KLRS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6,579.4% (avg: 12%), ROE -15.8% (avg: 15%), current ratio 12.19 (avg: 2).